Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

Kenya has the seventh-largest number of people living with HIV in the world, at around 1.4 million, according to World Health ...

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

The United States’ shutdown of HIV/Aids funding may harm global Aids programmes irreparably, jeopardising millions of lives ...

We’re rationing HIV medications now,” Christopher Mulela, a nurse at our Matero clinic in Zambia, told me quietly. “Patients ...

During the opening day of the Conference on Retroviruses and Opportunistic Infections, Rebecca Denison, a decades-long HIV ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.

PEPFAR, a global program to combat AIDS, faces an existential threat due to partisan politics, but Congress has an opportunity to reform the program and ensure its continued success.

A bill filed in Springfield would allow doctors to prescribe some HIV medication without needing prior authorization.